Baylor Research Institute

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Université Paris Est Creteil Val De Marne

Anne-Laure Flamar

Gerard Zurawski

Jacques F Banchereau

Sandra M Zurawski

Yves Levy

Eynav Klechevsky

Monica Montes

SangKon Oh

Peter Klucar

Keiko Akagawa

Amanda Cobb

Holly Mead

Gerald Zurawski

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Fusion proteins comprising an anti-CD40 antibody and cancer antigens

Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

Methods and compositions for treating and preventing HIV

Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides

Antigen presenting cell targeted anti-viral vaccines

The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells

The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.

Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef

Fusion proteins comprising antibody and HPV E6 and E7 antigens

Anti-CD40 targeted fusion proteins

Fusion protein with HIV antigen

Growing community of inventors

Dallas, TX, United States of America

Anne-Laure Flamar